Navigation Links
Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
Date:2/14/2008

PITTSBURGH, Feb. 14 /PRNewswire-FirstCall/ -- In response to several inquiries, Mylan Inc. (NYSE: MYL) confirmed today that its matrix design Fentanyl Transdermal System (FTS) is not part of the widespread recall being conducted by Ortho-McNeil-Janssen Pharmaceuticals, Inc. Ortho-McNeil reported that all lots of 25 mcg/hr Duragesic(R) CII patches sold by PriCara in the United States and all 25 mcg/hr Fentanyl patches sold by Sandoz Inc. in the United States are being voluntarily recalled as a precaution from wholesalers and pharmacies because they may have a cut along one side of the drug reservoir within the patch. The result is possible release of Fentanyl gel from the gel reservoir into the pouch in which the patch is packaged, exposing patients or caregivers directly to Fentanyl gel.

Unlike all other U.S. marketed Fentanyl patches, Mylan's FTS is a matrix patch, not a reservoir patch, and therefore does not leak.

Mylan Vice Chairman and CEO Robert J. Coury commented: "We have always believed that our Fentanyl Transdermal System is differentiated from all other Fentanyl patches in the U.S. market because of its unique matrix design. This is an important product characteristic that should be recognized and understood when choosing a Fentanyl Transdermal System."

Mylan's FTS was the first generic Class II narcotic transdermal product approved by the U.S. Food and Drug Administration.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey, L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas. For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Restores Availability of Generic Levothyroxine in Florida
2. Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
3. Mylan Declares Quarterly Preferred Stock Dividend
4. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
5. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
6. Mylan Sets Date of 2008 Annual Meeting
7. Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
8. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
9. Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock
10. Mylan Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock
11. Mylan Announces Appointment of Joseph F. Haggerty as Senior Vice President and Global General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... American ... conference coverage on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, a ... with the April edition of American Veterinarian™. , “We look forward ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... research products enables researchers to pursue the recent RNA methylation “gold rush” with ... In light of the newfound characteristics of N6-methyladenosine, or m6A , RNA ...
(Date:3/27/2017)... , ... March 27, 2017 , ... According to the ... cancer, including all stages, is more than 95%. Once the cancer spreads to other ... than 30%. To find out how to avoid this latter group, tune in to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending LLC announced ... litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil No. 1:14-CV-00121-CW/ ... to announce that we have now reached a settlement agreement regarding the ongoing ...
(Date:3/27/2017)... HOUSTON, Texas (PRWEB) , ... March 27, 2017 , ... ... and hard of hearing, is bringing its latest products to the Deaf Seniors of ... attendees will have the opportunity to meet with knowledgeable ASL friendly staff from Harris ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  Cryoport, Inc. (NASDAQ: CYRX, ... intends to offer shares of common stock in an ... on file with the Securities and Exchange Commission (the ... conditions, and there can be no assurance as to ... as to the actual size or terms of the ...
(Date:3/27/2017)... 27, 2017  A new survey from ... Medicare,s Competitive Bidding Program (CBP) significantly reduced beneficiary choice ... lack of choice forces beneficiaries to switch to unfamiliar ... consequences. AADE,s survey is the latest ... others pointing out the inherent problems with the CBP. ...
(Date:3/27/2017)... March 27, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ... 8IS) Invictus MD is pleased to announce it has ... trading on the TSX Venture Exchange.  ... a year of significant achievements for Invictus-MD. Some of ... crops at AB Laboratories Inc. ("AB Labs"), a Licensed ...
Breaking Medicine Technology: